Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
Generation Bio Co. - Common stock (GBIO)
Company Research
Source: GlobeNewswire
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results."Our selective, redosable cell-targeted lipid nanoparticle (ctLNP) delivery system enables precise modulation of T cells with siRNA, opening mechanisms that can powerfully reduce or eliminate autoreactive T cell activity while supporting immune balance,” said Geoffrey McDonough, M.D., chief executive officer of Generation Bio. “This innovative approach could allow us to addres
Show less
Read more
Impact Snapshot
Event Time:
GBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GBIO alerts
High impacting Generation Bio Co. - Common stock news events
Weekly update
A roundup of the hottest topics
GBIO
News
- Generation Bio (NASDAQ:GBIO) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- ‘Zombie' biotech buyer Xoma to acquire Generation Bio [Yahoo! Finance]Yahoo! Finance
- Generation Bio (NASDAQ:GBIO) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $5.50 price target on the stock, down previously from $7.00.MarketBeat
- NodThera Appoints Geoff McDonough, M.D., as Independent Board Member [Yahoo! Finance]Yahoo! Finance
- NodThera Appoints Geoff McDonough, M.D., as Independent Board MemberGlobeNewswire
GBIO
Earnings
- 11/5/25 - Beat
GBIO
Sec Filings
- 12/16/25 - Form SC
- 12/15/25 - Form SC14D9C
- 12/15/25 - Form 8-K
- GBIO's page on the SEC website